NEW YORK (GenomeWeb) – Biocept said today that Columbia University Medical Center is planning a study that will evaluate its Target Selector liquid biopsy platform for detecting leptomeningeal metastases in patients with breast cancer.

LM is a condition in which cancer cells gain access to the cerebral spinal fluid, allowing them to seed metastases in the nerve tissue of the spine and brain.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.